Results 191 to 200 of about 912,573 (281)

Endoscopic-assisted transoral atlantoaxial joint release using plasma radiofrequency ablation in management of irreducible atlantoaxial dislocation: a proof-of-concept case series with technical notes. [PDF]

BMC Surg
Li Z, Chen R, Chen R, Zheng Q, Chen Z, Chen C, Xu W.   +6 more
europepmc   +1 more source

Childhood Maltreatment and Cognitive Functioning in Bipolar Disorder: A Systematic Review and Meta‐Analysis

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 315-338, May 2026.
ABSTRACT Aims Characterising the association between childhood maltreatment (CM) and cognitive functioning in bipolar disorder (BD) is crucial for improving the understanding of how early environmental risk factors impact the presentation of the disorder.
Natalia E. Fares‐Otero, Anaid Pérez‐Ramos, Ricardo Lopez‐Escribano, Sara Martin‐Parra, Luis Alameda, Sarah L. Halligan, Kamilla Woznica Miskowiak, Eduard Vieta   +7 more
wiley   +1 more source

Deletion in CACNA1F gene causes X-linked progressive retinal atrophy in English Cocker Spaniel dogs. [PDF]

BMC Vet Res
Bionda A, Liotta L, Floridia V, Niggel JK, Giretto D, Crepaldi P, Aguirre GD, Murgiano L.   +7 more
europepmc   +1 more source

Predicting Response to Pro‐Cognitive Interventions in Mood Disorders: A Systematic Review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 374-401, May 2026.
ABSTRACT Introduction Major depressive disorder (MDD) and bipolar disorder (BD) are often associated with persistent cognitive deficits that impair psychosocial functioning. While pro‐cognitive interventions show promise, trial findings are inconsistent, potentially due to baseline factors influencing treatment response.
Dimosthenis Tsapekos, Michail Kalfas, Johanna M. Schandorff, Caterina del Mar Bonnin, Christopher R. Bowie, Vicent Balanzá‐Martínez, Katherine E. Burdick, Andre F. Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Gregor Hasler, Lars V. Kessing, Hanne L. Kjærstad, Beny Lafer, Kathryn E. Lewandowski, Carlos López‐Jaramillo, Anabel Martinez‐Aran, Roger S. McIntyre, Richard J. Porter, Scot E. Purdon, Ayal Schaffer, Paul R. A. Stokes, Tomiki Sumiyoshi, Ivan J. Torres, Tamsyn E. Van Rheenen, Lakshmi N. Yatham, Jeff Zarp, Allan H. Young, Eduard Vieta, Kamilla W. Miskowiak   +30 more
wiley   +1 more source

Evaluating contributions of progressive ratio analysis to economic metrics of demand. [PDF]

J Exp Anal Behav
Lambert JM, Osina MA, Staubitz JL, Reed DD, Madden GJ.   +4 more
europepmc   +1 more source

Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST)

BJU International, Volume 137, Issue 5, Page 886-894, May 2026.
Objectives To evaluate basal‐luminal cell of origin subtyping using Prediction Analysis of Microarray of 50 genes (PAM50) genomic classification profiles for predicting disease progression in men undergoing active surveillance (AS) for prostate cancer (PCa).
Ankur Malpani, Jonathan T. Ryan, Hui Yu, Nachiketh Soodana‐Prakash, Archan Khandekar, Tarek Ajami, Adam Williams, Zoe Szczotka, Mohammed Alshalalfa, Yangyang Hao, Elai Davicioni, Sanjaya Swain, Oleksandr N. Kryvenko, Alan Dal Pra, Radka Stoyanova, Sandra Gaston, Alan Pollack, Brandon A. Mahal, Matthew Abramowitz, Bruno Nahar, Chad R. Ritch, Bruce Kava, Mark L. Gonzalgo, Dipen J. Parekh, Sanoj Punnen   +24 more
wiley   +1 more source

Effects of One Season of Rugby on the Neurological Integrity of Male Adolescent Players. [PDF]

Sports Med Open
Henley S, Spriggs N, Kabaliuk N, Stitt D, Swale A, Xu C, Mangan K, Hamlin M, Masters R, Melzer T, Basu A, Anderson T, Snell D, Clark A, Alexander K, Holdsworth S, Draper N.   +16 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Phylogenetic systematics of Juncaceae. [PDF]

Am J Bot
Kenny RJ, Záveská Drábková L, Potter D.   +2 more
europepmc   +1 more source

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy.
Shan Pan, Teresa Tsakok, Ruoheng Wei, Nick Dand, Floris C. Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Angela Pushpa‐Rajah, Alice Russell, Ali Alsharqi, Gabrielle Becher, Ruth Murphy, Shyamal Wahie, Andrew Wright, Christopher E. M. Griffiths, Nick J. Reynolds, Jonathan Barker, Richard B. Warren, A. David Burden, Theo Rispens, Satveer K. Mahil, Joseph F. Standing, Catherine H. Smith, on behalf of the BADBIR Study Group, the BSTOP Study Group and the PSORT Consortium, Marilyn Benham, Sagair Hussain, Brian Kirby, Linda Lawson, Kathleen McElhone, Anthony Ormerod, Caroline Owen, Michael R. Barnes, Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne   +38 more
wiley   +1 more source